Treatment of Akathisia in Patients with Dementia

Introduction to Akathisia Management

The American Academy of Sleep Medicine recommends transitioning to melatonin at a dose of 3-15 mg with gradual dose increase in patients with dementia who are unresponsive to clonazepam and dekinet for akathisia treatment 1, 2
Clonazepam has significant limitations in elderly patients with dementia due to a high risk of side effects, including sedation, cognitive impairment, falls, and memory worsening, as noted by the American Geriatrics Society 3, 1
Benzodiazepines, including clonazepam, are considered potentially inappropriate medications in elderly patients with dementia according to the Beers criteria by the American Geriatrics Society 1, 3

The American Academy of Sleep Medicine suggests starting with immediate-release melatonin at a dose of 3 mg before bedtime and gradually increasing the dose in 3 mg increments until an effect is achieved or a maximum dose of 15 mg is reached 1, 2
Melatonin is a preferred option for elderly patients (>50 years) with neurodegenerative diseases, as it causes only mild sedation, according to the American Academy of Sleep Medicine 1
Rivastigmine (an acetylcholinesterase inhibitor) may be particularly useful for akathisia in patients with dementia, as recommended by the American Academy of Sleep Medicine, and should be started at a low dose and titrated according to the instructions, considering possible side effects (nausea, diarrhea, bradycardia) 1, 2

Ensuring a safe environment for the patient's sleep and rest is crucial, as suggested by the American Academy of Sleep Medicine 4
Minimizing the use of medications with anticholinergic properties, which can exacerbate cognitive impairment, is recommended by the Alzheimer's Association 5
Considering group cognitive stimulation therapy for patients with mild and moderate dementia may be beneficial, as noted by the Alzheimer's Association 5

Repeated prescription or dose increase of clonazepam should be avoided due to the high risk of side effects in elderly patients with dementia (sedation, falls, cognitive impairment), as warned by the American Geriatrics Society and the American Academy of Sleep Medicine 3, 1
When using melatonin, monitoring for possible side effects such as vivid dreams and sleep fragmentation is necessary, according to the American Academy of Sleep Medicine 1, 2
Regularly assessing the effectiveness of therapy and adjusting medication doses is crucial, as recommended by the Mayo Clinic Proceedings 3